Actavis (NYSE: ACT) announced that the European Commission has granted Actavis' subsidiary Durata Therapeutics International B.V., marketing authorization for XYDALBA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE